Effects of Interferon a 2a on Incidence of Hepatocellular Carcinoma in Chronic Active Hepatitis without Cirrhosis

Kurume Medical Journal

Volumn 44, Issue 3, 1997, Pages 171-177

  Sata, Michio ^a   Ide, Tatsuya ^a   Akiyoshi, Fuyuhiko ^a   Fukuizumi, Kunitaka ^a   Noguchi, Seiji ^a   Shirachi, Miki ^a   Sasaki, Masaru ^a   Uchimura, Yasuyo ^a   Suzuki, Hiroshi ^a   Tanikawa, Kyuichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic active hepatitis C; Hepatocellular carcinoma; Interferon therapy; Liver cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTICLE; CANCER INCIDENCE; CHRONIC ACTIVE HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS, CHRONIC; HUMANS; INCIDENCE; INTERFERON ALFA-2A; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 0030816917     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.44.171     Document Type: Article

References (20)

1. Alberiti A, Morsica G, Chemello L, Cavalletto D, Noventa F et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340:697-698.
2. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW et al. Isolation of a cDNA clone derived from a blood-born non-A, non-B viral hepatitis genome. Science 1989; 244:359-362.
3. Di Bisceglie AM, Martin P, Kassianides C, Lisker Melman M, Murray L et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, doubleblind placebo-controlled trial. N Engl J Med 1989; 321:1506-1510.
4. Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K et al. Anti-oncogenic and oncogenic potentials interferon regulatory factors-1 and -2. Science 1993; 259:971-974.
5. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986; 315:1575-1578.
6. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671-675.
7. Kuo G, Choo Q-L, Alter HJ, Gitnick GL, Redeker AG et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244:362-364.
8. Lai C-L, Lau JYN, Wu P-C, Ngan H, Chung H-T et al. Recombinant interferon- α in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17:389-394.
9. Nishiguchi S, Kuroki S, Nakatani S, Morimoto H, Takeda T et al. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051-1055.
10. Nishioka K, Watanabe J, Furuta S, Tanaka E, Suzuki H et al. Antibody to the hepatitis C virus in acute hepatitis C and chronic liver disease in Japan. Liver 1991; 11:65-70.
11. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12:680-687.
12. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87:6547-6549.
13. Sakamuro D, Furukawa T, and Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995; 69:3893-3896.
14. Shindo M, Di Bisceglie AM, and Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with α -interferon. Hepatology 1992; 15:1013-1016.
15. Takano S, Yokosuka O, Imazeki F, Tagawa M, and Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 1995; 21:650-655.
16. Takeda T, Nishiguchi S, Kuroki T, Kobayashi K, Hasuma T et al. Reduction by interferon-α of levels of C-myc protein and DNA synthesis in a human hepatoma cell line mediated by inhibition of putrescine synthesis. Biochem Biophys Res Commun 1991; 178:378-384.
17. Tarao K, Shimizu A, Ohkawa S, and Tamai S. I. Primary hepatocellular carcinoma. Establishment of a high-risk group. 5. Prediction of carcinoma developed from liver cirrhosis - Liver cirrhosis C-. J Jpn Soci Int Med 1995; 84:23-29. (in Japanese)
18. Tarao K, Hoshino H, Shimizu A, Ohkawa S, Nakamura Y et al. Role of increased DNA synthesis activity of hepatocytes in multicentric hepatocarcino-genesis in residual liver of hepatectomized cirrhotic patients with hepatocellular carcinoma. Jpn J Cancer Res 1994; 85:1040-1044.
19. Tarao K, Shimizu A, Harada M, Ohkawa S, Okamoto N et al. In Vitro uptake of bromodeoxyuridine by human hepatocellular carcinoma and its relation to histological findings and biologic behavior. Cancer 1991; 68:1789-1794.
20. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-1801.